{"id":"W4407176823","doi":"10.3390/cancers17030522","title":"Real-World Efficacy and Toxicity of Ipilimumab and Nivolumab as First-Line Treatment of Metastatic Renal Cell Carcinoma (mRCC) in a Subpopulation of Elderly and Poor Performance Status Patients","year":2025,"lang":"en","type":"article","venue":"Cancers","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre hospitalier universitaire de Québec; Sunnybrook Health Science Centre; Centre Hospitalier de l’Université de Montréal; McMaster University; Alberta Health Services; Health Sciences Centre; Capital District Health Authority; University Health Network; CancerCare Manitoba; University of Alberta; Queen Elizabeth II Health Sciences Centre; Juravinski Cancer Centre; McGill University Health Centre; University of Ottawa","funders":"EMD Serono; Ipsen; Astellas Pharma; Eisai; Seagen; Advanced Accelerator Applications; Genentech; AstraZeneca; Pfizer; Amgen","keywords":"Medicine; Nivolumab; Ipilimumab; Renal cell carcinoma; Sunitinib; Internal medicine; Cohort; Toxicity; Oncology; Kidney cancer; Population; Performance status; Expanded access; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003371735,0.0002346914,0.0006574096,0.0003600497,0.0002566705,0.0009186972,0.0005225519,0.0004306267,0.0006613712],"category_scores_gemma":[0.005329401,0.000166394,0.001254641,0.00055613,0.0003893395,0.0005090798,0.0004459071,0.0005417874,0.00008912987],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002697168,"about_ca_system_score_gemma":0.001248226,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.009286333,"about_ca_topic_score_gemma":0.01316224,"domain_scores_codex":[0.9982715,0.0007732128,0.0001418566,0.0003151878,0.0003381365,0.0001602243],"domain_scores_gemma":[0.9958269,0.0008443524,0.002375182,0.000229165,0.0002390621,0.0004853288],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.04475718,0.0009243429,0.9282822,0.0002695745,0.002937322,0.0001818466,0.0001825607,0.003344296,0.001476844,0.0001031541,0.001162034,0.01637856],"study_design_scores_gemma":[0.001889858,0.007024242,0.9860839,0.00004058695,0.0009405469,0.0002838569,0.0001179688,0.001986682,0.0005979406,0.00005417658,0.0009516115,0.00002863549],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9984889,0.0005718261,0.00004441826,0.00006231654,0.000006470975,0.00002600519,0.0006103089,0.000002386048,0.0001873186],"genre_scores_gemma":[0.9987549,0.0001202934,0.00005782609,0.00004316419,0.00001069865,0.00002390856,0.0009450624,8.57577e-7,0.00004328819],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009286333,"threshold_uncertainty_score":0.01956946,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01895800621687527,"score_gpt":0.2740941849173307,"score_spread":0.2551361787004554,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}